Wegener's granulomatosis: The current view

Frank Moosig; Peter Lamprecht; Wolfgang L. Gross

doi:10.1007/s12016-007-8067-5

Wegener's granulomatosis: The current view

Frank Moosig, Peter Lamprecht^*, Wolfgang L. Gross

^*Corresponding author for this work

Clinic of Rheumatology

26 Citations (Scopus)

Abstract

In the last few years, substantial progress has been achieved in elucidating the pathogenesis of Wegener's granulomatosis. Several genetic risk factors have been described. The structure of the granuloma and its possible function as ectopic lymphoid tissue have been defined. Furthermore, the consecutive immunopathological reactions leading to induction of PR3-antineutrophil cytoplasmic antibodies (ANCA) and the role of ANCA itself is getting clearer. However, the initial events leading to granuloma formation are still widely unknown. Concerning therapy, the significance of the so-called biological agents (TNF-α-blockers, Rituximab) still has to be defined.

Original language	English
Journal	Clinical Reviews in Allergy and Immunology
Volume	35
Issue number	1-2
Pages (from-to)	19-21
Number of pages	3
ISSN	1080-0549
DOIs	https://doi.org/10.1007/s12016-007-8067-5
Publication status	Published - 10.2008

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12016-007-8067-5

Cite this

@article{d8c863c82e5a49d0b5541191abe859d1,

title = "Wegener's granulomatosis: The current view",

abstract = "In the last few years, substantial progress has been achieved in elucidating the pathogenesis of Wegener's granulomatosis. Several genetic risk factors have been described. The structure of the granuloma and its possible function as ectopic lymphoid tissue have been defined. Furthermore, the consecutive immunopathological reactions leading to induction of PR3-antineutrophil cytoplasmic antibodies (ANCA) and the role of ANCA itself is getting clearer. However, the initial events leading to granuloma formation are still widely unknown. Concerning therapy, the significance of the so-called biological agents (TNF-α-blockers, Rituximab) still has to be defined.",

author = "Frank Moosig and Peter Lamprecht and Gross, {Wolfgang L.}",

year = "2008",

month = oct,

doi = "10.1007/s12016-007-8067-5",

language = "English",

volume = "35",

pages = "19--21",

journal = "Clinical Reviews in Allergy and Immunology",

issn = "1080-0549",

number = "1-2",

}

TY - JOUR

T1 - Wegener's granulomatosis: The current view

AU - Moosig, Frank

AU - Lamprecht, Peter

AU - Gross, Wolfgang L.

PY - 2008/10

Y1 - 2008/10

N2 - In the last few years, substantial progress has been achieved in elucidating the pathogenesis of Wegener's granulomatosis. Several genetic risk factors have been described. The structure of the granuloma and its possible function as ectopic lymphoid tissue have been defined. Furthermore, the consecutive immunopathological reactions leading to induction of PR3-antineutrophil cytoplasmic antibodies (ANCA) and the role of ANCA itself is getting clearer. However, the initial events leading to granuloma formation are still widely unknown. Concerning therapy, the significance of the so-called biological agents (TNF-α-blockers, Rituximab) still has to be defined.

AB - In the last few years, substantial progress has been achieved in elucidating the pathogenesis of Wegener's granulomatosis. Several genetic risk factors have been described. The structure of the granuloma and its possible function as ectopic lymphoid tissue have been defined. Furthermore, the consecutive immunopathological reactions leading to induction of PR3-antineutrophil cytoplasmic antibodies (ANCA) and the role of ANCA itself is getting clearer. However, the initial events leading to granuloma formation are still widely unknown. Concerning therapy, the significance of the so-called biological agents (TNF-α-blockers, Rituximab) still has to be defined.

UR - http://www.scopus.com/inward/record.url?scp=55249104543&partnerID=8YFLogxK

U2 - 10.1007/s12016-007-8067-5

DO - 10.1007/s12016-007-8067-5

M3 - Short survey

C2 - 18172776

AN - SCOPUS:55249104543

SN - 1080-0549

VL - 35

SP - 19

EP - 21

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

IS - 1-2

ER -

Wegener's granulomatosis: The current view

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this